Novartis Oncology is conducting global development initiatives for key molecules encompassing a broad range of malignancies. Open partnerships within the oncology care community enable us to conduct high-quality clinical trials with competitive timelines and aid in the discovery of new uses of our medicines to benefit patients.
- Connecting to lifecycle management program information
- The WIDE program
The WIDE (Worldwide Initiative to Develop Everolimus) Program is a global initiative that encompasses a broad range of malignancies. Through this program, Novartis Oncology is conducting clinical studies of everolimus as a single agent and in combination with other anticancer treatments.
This website provides a concise overview of Phase II and Phase III clinical trials with everolimus (RAD001). All of these oncology trials are being conducted within the WIDE Program—and are either enrolling or will soon be enrolling participants. We hope that you will keep these clinical trials in mind when treating oncology patients who may be appropriate candidates for participation in a clinical trial.
- PRI3M Trials
PRI3M (Pioneering Research of PI3K inhibitors in Malignancies) is a program of clinical research sponsored by Novartis.
Here you will find information about the PI3K/Akt/mTOR pathway and the clinical trials with the Novartis PI3K inhibitor buparlisib (BKM120), which are currently enrolling patients with metastatic Breast cancer and Head and Neck Squamous Cell Cancer (HNSCC.)
- The GOLD trials
The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, such as renal cell carcinoma (RCC), breast cancer, gastric cancer, hepatocellular carcinoma (HCC), multiple myeloma, and urothelial cancer. Through this program, Novartis is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.1
1. Data on file. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2010.
ClinicalTrials.gov is a website service provided by the United States National Institutes of Health (NIH). The NIH, through its National Library of Medicine, has developed this website in collaboration with the Food and Drug Administration (FDA), as a result of the FDA Modernization Act, which was passed into law in November 1997.
- IFPMA clinical trials portal
This service is provided by the IFPMA, on behalf of its Member Companies and Associations. The portal has been designed as a single entry allowing you to search for comprehensive information on ongoing clinical trials (registry) or results of completed trials (database) conducted by the innovative pharmaceutical industry.